Oncotherm

Oncotherm is a medical-device brand associated with oncothermia, a form of therapeutic hyperthermia intended for use in cancer treatment. The devices are produced by Oncotherm Ltd., a company founded in Hungary in 1988 by Prof. Dr. András Szász. The brand’s central technical and therapeutic concept is that cancerous tissue can respond differently to externally applied electrical energy than surrounding healthy tissue. In the company’s methodology, tissue impedance is important in determining how the applied energy is absorbed. Tumor tissue is described as having lower impedance than adjacent tissues, allowing the treatment to preferentially transmit and concentrate energy in the cancerous lesion. The approach is characterized by the company as a form of self-focusing, reducing the need for a separate external focusing system. Oncotherm’s corporate structure changed in 2002 after the company received investment from a German business. It was subsequently reorganized as a German-Hungarian organization comprising Oncotherm Hungary Ltd. and Oncotherm GmbH. This structure reflected the brand’s cross-border operating footprint and its reported concentration of installations in Germany and South Korea. The available reference material identifies the EHY-2000 and EHY-2030 as its principal medical-device products. Both are hyperthermia systems that use electrical fields and thermoelectric effects in the delivery of treatment. According to the available reference material, more than 450 Oncotherm devices had been placed into operation and the systems had been used in more than 400,000 treatments. These figures describe reported device deployment and treatment volume, but the source does not provide a specific measurement date or a detailed breakdown by country, institution, indication, or clinical outcome. The same material states that the devices are not approved by the United States Food and Drug Administration, so the brand’s regulatory position in the United States differs from its reported use in other markets. Oncotherm is positioned primarily as a specialized medical-technology supplier rather than as a consumer healthcare brand. Its identity is tied to the development and supply of equipment for oncothermia or electro-hyperthermia, with a technical emphasis on selective energy absorption by tumor tissue. The available information does not establish a complete product portfolio, current ownership, headquarters, financial performance, public listing, or a comprehensive account of clinical indications and regulatory clearances. Consequently, the brand should be understood from the documented material as a specialist oncology-device business whose principal known offerings are the EHY-2000 and EHY-2030 systems.

Oncotherm Ltd. was founded in Hungary in 1988 by Prof. Dr. András Szász. From its beginning, the company’s work was centered on oncothermia, a hyperthermia-based treatment methodology using electrically delivered energy. The approach rests on the proposition that tissue characteristics, particularly impedance, influence how energy is transmitted and absorbed. Oncotherm’s methodology describes malignant tissue as having lower impedance than surrounding tissue. On that basis, the treatment is intended to favor absorption by the tumor and produce a degree of internal or self-directed energy concentration without requiring external focusing equipment. A significant organizational development occurred in 2002, when the company received investment from a German company. Following the investment, the business was reorganized into a German-Hungarian structure consisting of Oncotherm Hungary Ltd. and Oncotherm GmbH. The reorganization provided the basis for the brand’s cross-border corporate identity and corresponds with the reported prominence of Germany among the markets in which its equipment was installed. The principal devices identified in the available historical material are the Oncotherm EHY-2000 and EHY-2030. These systems are described as hyperthermia devices that use thermoelectric effects generated through electrical fields. They represent the practical expression of the company’s oncothermia methodology: applying controlled electrical energy in a clinical treatment setting with the stated aim of preferentially affecting tumor tissue. Oncotherm’s equipment has reportedly been installed in more than 450 sites or institutions, with Germany and South Korea identified as the main locations in the available account. The systems are also reported to have been used for more than 400,000 treatments. The reference does not specify the date on which these totals were measured, nor does it provide a complete list of installations, treatment indications, clinical outcomes, or regulatory jurisdictions. The available material further states that Oncotherm devices are not approved by the United States Food and Drug Administration. This is an important qualification when describing the brand’s international presence because reported use in Germany and South Korea does not establish authorization in the United States. No reliable information in the supplied sources identifies current executives, ownership, annual revenue, stock-market listing, headquarters address, or a broader present-day product range. The documented history therefore presents Oncotherm as a Hungary-origin specialist medical-device brand that developed an international presence through oncothermia equipment and a German-Hungarian corporate structure.

• 2002

  German investment and corporate reorganization

  [1]Oncothermen.wikipedia.org

  After receiving investment from a German company, Oncotherm was reorganized as a German-Hungarian organization consisting of Oncotherm Hungary Ltd. and Oncotherm GmbH.

• 1988

  Oncotherm founded in Hungary

  [1]Oncothermen.wikipedia.org

  Oncotherm Ltd. was founded in Hungary by Prof. Dr. András Szász, establishing the company that would develop and produce oncothermia medical devices.

• International deployment of treatment systems

  [1]Oncothermen.wikipedia.org

  The available reference reports that more than 450 devices were placed into operation, primarily in Germany and South Korea, and that the systems were used in more than 400,000 treatments. The source does not provide a date for these figures.

A specialist medical-technology brand focused on oncothermia and electro-hyperthermia equipment, emphasizing electrically delivered heat and the differential impedance characteristics of tumor tissue.

• Electro-hyperthermia medical device

  Oncotherm EHY-2000

  The EHY-2000 is one of Oncotherm’s principal oncothermia systems. It is described as a hyperthermia device that uses electrical fields and thermoelectric effects to deliver treatment energy. Within the company’s methodology, the system is intended to exploit differences in tissue impedance so that energy is preferentially absorbed by tumor tissue relative to surrounding tissue. The available source does not specify its launch date, technical specifications, indications, or regulatory clearances by jurisdiction.

• Electro-hyperthermia medical device

  Oncotherm EHY-2030

  The EHY-2030 is identified as another main Oncotherm hyperthermia device. Like the EHY-2000, it uses electrical-field-based thermoelectric effects in the delivery of oncothermia treatment. The brand’s stated rationale is that tumor tissue has different impedance characteristics from nearby healthy tissue, enabling a degree of treatment self-focusing. The supplied reference does not establish the model’s launch year, detailed capabilities, approved indications, or current availability.

• 2002

  Creation of a German-Hungarian corporate structureStrategy

  Background

  Oncotherm received investment from a German company during a period when the business was developing an international presence for its medical-device activities.

  Action taken

  The company was reorganized into Oncotherm Hungary Ltd. and Oncotherm GmbH, creating a German-Hungarian operating structure.

  Aftermath

  Germany became one of the principal reported locations for deployed Oncotherm devices. The available source does not provide ownership percentages, investment value, or later corporate changes.

  Source

1. 1Oncothermen.wikipedia.org